SARS-CoV-2 Acute Respiratory Disease Clinical Trial
Official title:
Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population
The COVID-19 pandemic caused by SARS-CoV-2 since December 2019 has caused more than 210 million cases worldwide as of September 1, 2021. New Caledonia (NC) is an ultramarine French territory in the South Pacific so far relatively spared by this pandemic thanks to the establishment of a health lock. The vaccination campaign started locally on 20/01/2021 with the exclusive use of Pfizer's COMIRNATY mRNA vaccine. Vaccination is now offered to anyone over the age of 12. Vaccination against COVID-19 will be mandatory in New Caledonia as of October 31, 2021 for certain exposed populations and for the entire adult population as of December 31, 2021. Clinical trials of COVID-19 vaccines, including those of mRNA vaccines, have taken care to maintain ethnic diversity within their samples. Efficacy studies have not shown a significant difference in the efficacy of Pfizer COMIRNATY vaccine in white, black American, or Hispanic populations. The response of non-European non-Asian Oceanian populations to Pfizer COMIRNATY vaccination has not been specifically studied at this time. According to the 2019 census in New Caledonia, 41.2% of the population identified themselves as Kanak (Melanesian), 24% as European, 8.3% as Wallisian-Futunian (Polynesian), 11% as mestizo, and 8% as belonging to other communities including Tahitian (Polynesian), Indonesian, Ni-Vanuatu (Melanesian), and Vietnamese communities (8). Some recent data are in favor of a significant variability of susceptibility to pathogens in Oceanian populations, stemming from a genetic inheritance from Neanderthal man and his cousin Denisova man. In a context of vaccine hesitancy, it is therefore important to ensure that the immune response of the New Caledonian population (Melanesian, Polynesian, European or other communities) to vaccination against COVID-19 is similar to that of populations studied in large clinical trials.
Observational equivalence study with prospective data collection. Vaccinated subjects to be included will be identified in the vaccination centers in the Southern Province during the injection of the second dose. Information and consent collection. Completion of a questionnaire and collection of 4 mL of blood on a dry tube at M1 and M6 months. Testing for the presence of anti-SARS-CoV-2 antibodies by ELISA (anti-Spike and anti-Nucleoprotein). Return of the results of the serological analyses to the participants. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05063214 -
Muscle Evaluation of Patients Infected by the Coronavirus
|
||
| Not yet recruiting |
NCT05013034 -
Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients
|
Phase 2 | |
| Completed |
NCT04998253 -
Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2
|
Early Phase 1 | |
| Active, not recruiting |
NCT05167227 -
Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?
|
N/A | |
| Withdrawn |
NCT05393999 -
SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations
|
Phase 2 | |
| Completed |
NCT05142553 -
Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.
|
Phase 2 | |
| Recruiting |
NCT04929691 -
The CircumVent Project: A CPAP/O2 Helmet Solution for Non-Invasive Ventilation Among Patients With COVID-19
|
N/A | |
| Completed |
NCT05142514 -
Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)
|
Phase 2 | |
| Withdrawn |
NCT04894682 -
Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor
|
||
| Completed |
NCT04845048 -
Active Pharmacovigilance Study of Adsorbed COVID-19 (Inactivated) Vaccine
|
||
| Completed |
NCT05638178 -
The Corona Study of Middle Norway
|
||
| Not yet recruiting |
NCT05248373 -
Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05074121 -
NAC for Attenuation of COVID-19 Symptomatology
|
Phase 2 | |
| Completed |
NCT05305573 -
Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.
|
Phase 2 | |
| Completed |
NCT05042193 -
A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19
|
||
| Completed |
NCT04896866 -
Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP)
|
N/A | |
| Completed |
NCT04371471 -
Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
|
||
| Completed |
NCT05008562 -
How COVID-19 Effects to Muscle Mass Change ın ICU?
|
||
| Completed |
NCT04954157 -
Studies to Determine Whether Oxygen Sensing is Impaired in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients
|
N/A | |
| Recruiting |
NCT05133596 -
Study of the Evolution of Olfactory Disorders in Patients With Persistent Loss of Smell Following COVID-19
|
N/A |